TEGASEROD

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H23N5O
Molecular Weight	301.3867
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of TEGASEROD

Structure Search

SMILES

CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2

InChI

InChIKey=IKBKZGMPCYNSLU-RGVLZGJSSA-N

InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+

HIDE SMILES / InChI

Molecular Formula	C16H23N5O
Molecular Weight	301.3867
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:33:43 UTC 2023` Edited by `admin` on `Fri Dec 15 16:33:43 UTC 2023`
Record UNII	458VC51857
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEGASEROD

Official Name

English

1-[[(5-Methoxyindol-3-yl)methylene]amino]-3-pentylguanidine

Systematic Name

English

HYDRAZINECARBOXIMIDAMIDE, 2-((5-METHOXY-1H-INDOL-3-YL)METHYLENE)-N-PENTYL-, (2E)-

Systematic Name

English

Tegaserod [WHO-DD]

Common Name

English

TEGASEROD [MI]

Common Name

English

SDZ-HTF-919

Code

English

TEGASEROD [VANDF]

Common Name

English

HYDRAZINECARBOXIMIDAMIDE, 2-((5-METHOXY-1H-INDOL-3-YL)METHYLENE)-N-PENTYL-

Systematic Name

English

HTF919

Code

English

tegaserod [INN]

Common Name

English

TEGASEROD [USAN]

Common Name

English

TEGASEROD [EMA EPAR]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA06AX06

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

NDF-RT

N0000175815

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

LIVERTOX

925

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

WHO-ATC

A06AX06

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

NCI_THESAURUS

C66885

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

NDF-RT

N0000175816

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

WHO-ATC

A03AE02

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

Code System Code Type Description

INN

7606

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

DRUG CENTRAL

2579

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

LACTMED

Tegaserod

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

DAILYMED

458VC51857

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

EVMPD

SUB04713MIG

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

NCI_THESAURUS

C66583

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

RXCUI

139778

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

RxNorm

CAS

1044642-88-7

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

ALTERNATIVE

IUPHAR

226

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

ChEMBL

CHEMBL76370

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

FDA UNII

458VC51857

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

EPA CompTox

DTXSID6045955

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

PUBCHEM

135409453

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

SMS_ID

100000084790

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

MERCK INDEX

m10523

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

Merck Index

CHEBI

51043

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

WIKIPEDIA

TEGASEROD

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

DRUG BANK

DB01079

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

MESH

C105050

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

USAN

LL-61

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

CAS

145158-71-0

Created by admin on Fri Dec 15 16:33:43 UTC 2023 , Edited by admin on Fri Dec 15 16:33:43 UTC 2023

PRIMARY

Related Record Type Details


					E5XNT3RF5A

TEGASEROD MALEATE

SALT/SOLVATE -> PARENT

Amount:


					458VC51857

TEGASEROD

EXCRETED UNCHANGED

Comments:

Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine, primarily as the main metabolite.

Qualification:

FECAL

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					VK4SQL11C0

CYTOCHROME P450 1A2

METABOLIC ENZYME -> INHIBITOR

Qualification:

Ki

Amount:


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> INHIBITOR

Qualification:

Ki

Amount:


					7H1P16DG5J

5-HYDROXYTRYPTAMINE RECEPTOR 4

TARGET -> AGONIST

Amount:

Related Record Type Details


					XEM7FN2PHE

(2S,3S,4S,5R,6R)-3,4,5-TRIHYDROXY-6-(((E)-(5-METHOXY-1H-INDOL-3-YL)METHYLENEAMINO)-(N-PENTYLCARBAMIMIDOYL)AMINO)TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Comments:

In human liver slices, direct N-glucuronidation of tegaserod at the guanidine nitrogens (M43.2, M43.8, and M45.3) was found, with M43.8 being the major metabolite

Interaction Type:

MAJOR

Amount:


					5TV283T8KR

2-((5-HYDROXY-1H-INDOL-3-YL)METHYLENE)-N-PENTYLHYDRAZINECARBOXIMIDAMIDE

METABOLITE -> PARENT

Amount:


					H93626M6ED

(2S,3S,4S,5R,6R)-3,4,5-TRIHYDROXY-6-((N-((E)-(5-METHOXY-1H-INDOL-3-YL)METHYLENEAMINO)CARBAMIMIDOYL)-PENTYL-AMINO)TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Amount:


					X25VF4PO1W

.BETA.-D-GLUCOPYRANURONIC ACID, 1-(5-METHOXY-1H-INDOLE-3-CARBOXYLATE)

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA

Amount:


					GEO0WHY23Y

(2S,3S,4S,5R,6R)-3,4,5-TRIHYDROXY-6-((E)-(((2E)-2-((5-METHOXY-1H-INDOL-3-YL)METHYLENE)HYDRAZINO)-(PENTYLAMINO)METHYLENE)AMINO)TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Amount:

Related Record Type Details


					458VC51857

TEGASEROD

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC